Of the medical staff of our hospital 217 members at high risk for hepatitis B were immunized with an experimental hepatitis B vaccine and anti-HBs titers used to study the influence of two dosage schedules, age, and sex on immunogenicity. Participants were 34 years of age (mean; range, 20-61); they were divided into two groups and vaccinated three times. Group A received 42 lag HBsAg for each vaccination. Group B received 84 lag for the first and 21 lag for the second and third vaccinations. The seroconversion rate was 32.7% after the first, 78.8% after the second, and 95.7% after the third vaccination. The participants who failed to produce anti-HBs titer (3 IU/1; n = 9) or whose anti-HBs titers were below 50 IU/1 (n= 31) were vaccinated a fourth time. Only mild side effects of injections were observed in a third of all participants, usually in the form of a sore arm.
The studies of Szmuness et al. [21, 22] , Maupas et al. [12] , Crosnier et al. [2, 3] , and ReerinkBrongers et al. [18] demonstrated the safety and efficacy of active immunization against hepatitis B in homosexuals, children in Senegal, hemodialysis unit staff and patients, and volunteers. These populations are not only at high risk as far as morbidity and mortality of the acute illness is concerned, but also because of chronic viral hepatitis, liver cirrhosis, and primary liver cell carcinomaconditions which to date cannot be treated effectively.
In Europe, vaccination was especially recommended for health care personnel because they are at a higher risk for hepatitis B than is the normal population [4] . A non-or low-responder rate of 7%-10% was observed in healthy individuals, but these terms are not uniformly defined. Thus, many questions related to immunogenicity, sex and age dependence, and dosage schedule are still open for discussion in this particular group of individuals. We conducted a trial in high-risk personnel of a large medical school hospital using an experimental hepatitis B vaccine [24] , when commercial preparations were not yet available in Germany and safety was of great concern. We measured antiHBs titers in this trial to investigate aspects of immunogenicity of HBsAg, using two different dosage schedules against age and sex differences.
Methods

Participants
Trial participants were recruited from high-risk settings within our hospital, e.g., surgery, intensive care, hemodialysis, anesthesiology (Table 1) . Inclusion criteria were: no history of hepatitis B, negative serologic studies for all markers of hepatitis B virus infection or the presence of anti-HBs or anti-HBc alone, normal transaminase levels, and written informed consent. There were 217 participants in the study. The first 110 were assigned to group A (see below), the remaining 107 to group B. Groups A and B did not show statistically significant differences in terms of numbers, sex, and age (Table 2) .
Vaccine
The experimental vaccine administered in this trial consisted of purified 22 nm HBsAg particles absorbed onto aluminium hydroxide adjuvant. It was passed for clinical trials by the Ethics Committee of the Medical Department of the University of G6ttingen. Not only potency, but also safety as- 
Study Design
The vaccination included three injections of vaccine, the first two given 1 month apart and the third given 5 months after the first vaccination. Participants in group A received three injections of 42 gg HBsAg, participants in group B received 84 ~tg for the first and 2t txg HBsAg for the second and third injections. Thus, the total dose was identical in both groups. Adverse effect protocols and blood samples were obtained 3 weeks after each injection. The serum was tested for HBsAg, anti-HBs titer, antiHBc, and aminotransferases.
Participants whose anti-HBs titer was below 50 IU/1 after the third injection were regarded as low responders, and they were vaccinated a fourth time.
From 217 participants who were enrolled in the study, only six had to be excluded (one in group A, five in group B), all of them because of failure to appear for control studies. None of these six drop-outs had experienced notable side effects.
Laboratory and Statistical Methods'
Anti-HBs titers were measured in the laboratory of Prof. Thomssen, G6ttingen, by radioimmunoassay using the WHO standard as a reference. Levels of at least 3 IU/1 were regarded as positive, and defined seroconversion. Tests for HBsAG and anti-HBc were performed using commercially available radioimmunoassays in the laboratory of Prof. Habermehl, Berlin. Additionally, blood samples were measured for alanine and aspartate aminotransferases using a spectrophotometric procedure, according to the optimized standard methods of the Deutsche Gesellschaft ffir Klinische Chemie, using commercial kits. Statistical significance of differences between means was calculated with Student's t-test. 
Results
Immunogenicity and Revaccination
The No anamnestic responses were observed in six participants who were either anti-HBc or anti-HBs positive before vaccination.
Sex
The level of anti-HBs was dependent on the sex of the participants (Fig. 3) . In females the geometric mean after the third injection was 1 170 IU/1 (range, 0-137800); in males, only 171 (0-20000). This difference was statistically significant (P< 0.002). No statistically significant differences between males and females were found, however, as far as the seroconversion rates after the first vaccination are concerned. The proportion of nonresponders and low-responders in males and females and the response to revaccination is described in the previous paragraph.
Age
The level of anti-HBs was also dependent on the age of the participants (Fig. 4) . The younger the vaccine recipients were, the higher was the antiHBs titer produced after the third injection. In the age group 20-30 years, the geometric mean was 895 IU/1 anti-HBs (range, 0-137800); in the age group 31-40 years, 383 IU/1 (0-49590); in the age group 41-50 years, 241 IU/1 (0-16480); and in the age group of 51years and older, 154IU/1 (14-2930). The differences between the age groups 20-30 years and 31-40 years and 20-30 and 41-50 years were statistically significant (P<0.05). Higher age groups were too small to achieve statistical significance, but Fig. 4 clearly shows the trend to lower anti-HBs titers in the older age groups.
Variation of Dosage Schedule
Compared with group A the higher dose of HBsAg in group B did not have an important effect on the seroconversion rate after the first injection (Table 3). It was 36% in group B and 30% in group A, a difference which was not statistically significant. The geometric mean of the anti-HBs titer after the third injection in group B was 278 IU/1 (0-51 790) and thus significantly (P<0.05) lower than in group A with 891 IU/1 (0-137800) (Fig. 5) .
Adverse Effects
Only minor side effects occurred. Almost 30% of the participants complained about soreness of the arm at the injection site. Other complaints were: rash at the injection site, pruritus and elevated body temperature, in a few cases only. All adverse effects resolved within 2-4 days.
Discussion
Safety aspects played an important part in the preparation of the German experimental vaccine used in this trial [25] . In order to reduce the theoretically possible residual infectivity, a high formalin concentration of 1:500 was used for inactivation [24] . This procedure for selection and inactivation of the experimental vaccine leads to changes in antigenicity and immunogenicity of the vaccine, which are lower than those of the MSD vaccine (HB-Vax). While the geometric mean of anti-HBs levels after the third injection was only 428 IU/1 in our study, it is significantly higher when the MSD vaccine is used [28] . This is of practical importance in view of revaccination policy, since the initial anti-HBs titer was shown to predict the loss of protection after between 1 and 5 years [11] . As far as the seroconversion rates after the third injection are concerned, there is no difference between the experimental vaccine and the commercially available ones [2, 4, 23] .
In the context of our aim to study aspects of immunogenicity of HBsAg (such as genetic regulation of antibody response), the destruction of part of the antigenic epitopes may be of advantage. The detection of differences in genetic regulation could be facilitated, since it is well known that antibody responses are regulated on the single epitope level. As a consequence, compared with other studies [2, 5, 10, 12, 21] , we observe a relatively high percentage (19%) of non-and low-responders and their immune system is now being studied.
It is interesting to note that in six individuals with either anti-HBc or anti-HBs positive sera no anamnestic response was observed, indicating that these "antibodies" were probably not related to previous infection with hepatitis B virus. It is thus important to immunize such persons. One of the initial questions of our study was whether a modified immunization schedule with a higher first dose of 84 ~tg and lower successive doses of 21 gg would result in an earlier seroconversion. This was not the case. Seroconversion rates after the first injection were similar in groups A and B (Table 3) . In another study, using dosages different from ours, no significant differences in the seroconversion rates were observed with doses of 40, 20, and 10 gg HBsAg [10] . On the other hand, in this latter investigation, the levels of anti-HBs after the booster injection were dose-dependent. A 40-gg HBsAg dose resulted in higher anti-HBs titers than the 20-and 10-gg doses. This is in agreement with our findings that the anti-HBs levels after the third injection are lower with the dosage schedule 84-21-21 gg.
The immune response depended on sex and age of the participants. Women acquired significantly higher anti-HBs levels, and the older the vaccinees were the lower were the anti-HBs titers after the booster injection. This was statistically significant between the age groups 20-31/31-40 and 20-30/41-50 years, and Fig. 4 clearly shows this trend for the other age groups as well. These findings are similar to those of other authors [6, 8, 20, 21, 27 ], but only one author could demonstrate statistical significance [27] . Also, Wildgrube et al. [27] found a higher seroconversion rate in females and young vaccinees after the first injection, which we did not observe. Other studies have failed to demonstrate a dependency of the immune response on the sex of vaccinated health care workers [5] or Senegalese children [12] .
Nonresponders and low-responders (participants who had anti-t-IBs titers below 50 IU/1 after the third injection) received a fourth injection. It is known that a rapid decline in anti-HBs levels occurs within half a year after vaccination [11] and only persons with anti-HBs titers of 10 IU/1 or higher are judged to be protected against hepatitis B. After the fourth injection, six of nine of the nonresponders acquired anti-HBs and all the lowresponders showed a higher anti-HBs level. In uremic patients with a high proportion of nonresponders more frequent injections also resulted in a higher seroconversion rate [1] .
Only minor adverse effects were observed. Almost 30% of the participants complained about soreness of the arm at the injection site. Other side effects were a rash at the injection site, pruritus and temperature elevations, which were seen in a few cases only. Thus it can be concluded that the vaccine is safe and the adverse effects are similar to those after application of other vaccine preparations [22, 23, 27] .
Our results and other studies including experiments in mice [9, 13, 14, 15, 16, 26] suggest that responsiveness to hepatitis B vaccine might be genetically determined, but a clear marker could not yet be elucidated in man. This may in part be due to small groups and unsophisticated methodology. We have observed a relatively large group of non-/ low-responders to HBsAg vaccination who are currently being screened for immune markers. This and the observed influence of sex and age will not only have practical consequences for revaccination policy but also offers the possibility to study the genetic regulation of an immune response to a complex peptide antigen in man. New modalities to circumvent a genetically determined low antibody response are already conceivable, such as immunization with pre-S antigens [7, 17] , and this makes it more desirable to be able to predict the types of responders to conventional HBsAg vaccines.
